These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 21636135)
1. Varenicline prevents affective and cognitive exacerbation during smoking abstinence in male patients with schizophrenia. Liu ME; Tsai SJ; Jeang SY; Peng SL; Wu SL; Chen MC; Tsai YL; Yang ST Psychiatry Res; 2011 Nov; 190(1):79-84. PubMed ID: 21636135 [TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. Williams JM; Anthenelli RM; Morris CD; Treadow J; Thompson JR; Yunis C; George TP J Clin Psychiatry; 2012 May; 73(5):654-60. PubMed ID: 22697191 [TBL] [Abstract][Full Text] [Related]
3. Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Smith RC; Lindenmayer JP; Davis JM; Cornwell J; Noth K; Gupta S; Sershen H; Lajtha A Schizophr Res; 2009 May; 110(1-3):149-55. PubMed ID: 19251401 [TBL] [Abstract][Full Text] [Related]
4. Varenicline for smoking cessation: a placebo-controlled, randomized study. Wang C; Xiao D; Chan KP; Pothirat C; Garza D; Davies S Respirology; 2009 Apr; 14(3):384-92. PubMed ID: 19192221 [TBL] [Abstract][Full Text] [Related]
5. Effects of varenicline in adult smokers: a multinational, 24-week, randomized, double-blind, placebo-controlled study. Bolliger CT; Issa JS; Posadas-Valay R; Safwat T; Abreu P; Correia EA; Park PW; Chopra P Clin Ther; 2011 Apr; 33(4):465-77. PubMed ID: 21635992 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Oncken C; Gonzales D; Nides M; Rennard S; Watsky E; Billing CB; Anziano R; Reeves K Arch Intern Med; 2006 Aug 14-28; 166(15):1571-7. PubMed ID: 16908789 [TBL] [Abstract][Full Text] [Related]
7. Does varenicline worsen psychiatric symptoms in patients with schizophrenia or schizoaffective disorder? A review of published studies. Cerimele JM; Durango A J Clin Psychiatry; 2012 Aug; 73(8):e1039-47. PubMed ID: 22967780 [TBL] [Abstract][Full Text] [Related]
8. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Nides M; Oncken C; Gonzales D; Rennard S; Watsky EJ; Anziano R; Reeves KR Arch Intern Med; 2006 Aug 14-28; 166(15):1561-8. PubMed ID: 16908788 [TBL] [Abstract][Full Text] [Related]
9. Varenicline modulates spatial working memory deficits in smokers with schizophrenia. Wing VC; Wass CE; Bacher I; Rabin RA; George TP Schizophr Res; 2013 Sep; 149(1-3):190-1. PubMed ID: 23849883 [No Abstract] [Full Text] [Related]
10. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial. Anthenelli RM; Morris C; Ramey TS; Dubrava SJ; Tsilkos K; Russ C; Yunis C Ann Intern Med; 2013 Sep; 159(6):390-400. PubMed ID: 24042367 [TBL] [Abstract][Full Text] [Related]
11. Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. Hong LE; Thaker GK; McMahon RP; Summerfelt A; Rachbeisel J; Fuller RL; Wonodi I; Buchanan RW; Myers C; Heishman SJ; Yang J; Nye A Arch Gen Psychiatry; 2011 Dec; 68(12):1195-206. PubMed ID: 21810630 [TBL] [Abstract][Full Text] [Related]
12. Varenicline in prevention of relapse to smoking: effect of quit pattern on response to extended treatment. Hajek P; Tønnesen P; Arteaga C; Russ C; Tonstad S Addiction; 2009 Sep; 104(9):1597-602. PubMed ID: 19686530 [TBL] [Abstract][Full Text] [Related]
13. Effects of the alpha4beta2 partial agonist varenicline on brain activity and working memory in abstinent smokers. Loughead J; Ray R; Wileyto EP; Ruparel K; Sanborn P; Siegel S; Gur RC; Lerman C Biol Psychiatry; 2010 Apr; 67(8):715-21. PubMed ID: 20207347 [TBL] [Abstract][Full Text] [Related]
14. A double-blind randomized placebo-controlled pilot study of neuropsychiatric adverse events in abstinent smokers treated with varenicline or placebo. Garza D; Murphy M; Tseng LJ; Riordan HJ; Chatterjee A Biol Psychiatry; 2011 Jun; 69(11):1075-82. PubMed ID: 21295286 [TBL] [Abstract][Full Text] [Related]
15. Tobacco dependence treatment for hospitalized smokers: a randomized, controlled, pilot trial using varenicline. Steinberg MB; Randall J; Greenhaus S; Schmelzer AC; Richardson DL; Carson JL Addict Behav; 2011 Dec; 36(12):1127-32. PubMed ID: 21835552 [TBL] [Abstract][Full Text] [Related]
16. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Stapleton JA; Watson L; Spirling LI; Smith R; Milbrandt A; Ratcliffe M; Sutherland G Addiction; 2008 Jan; 103(1):146-54. PubMed ID: 18028247 [TBL] [Abstract][Full Text] [Related]